These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 1467322

  • 1. [Augmentation of therapeutic effect of adoptive immunotherapy through a synergy between transferred killer cells and host's fresh lymphocytes].
    Kan N, Yamasaki S, Harada T, Satoh K, Ichinose Y, Moriguchi Y, Kodama H, Ohgaki K.
    Hum Cell; 1992 Sep; 5(3):236-42. PubMed ID: 1467322
    [Abstract] [Full Text] [Related]

  • 2. [Experimental and clinical study of adoptive immunotherapy combined with preadministration of OK-432: a method to augment the therapeutic effect].
    Kan N, Okino T, Nakanishi M, Sato K, Mise K, Teramura Y, Yamasaki S, Hori T, Ohgaki K, Tobe T.
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1455-61. PubMed ID: 2786379
    [Abstract] [Full Text] [Related]

  • 3. [Clinical therapeutic effect of adoptive immunotherapy using IL-2-cultured autologous lymphocytes].
    Kan N, Okino T, Nakanishi M, Satou K, Mise K, Ohgaki K, Hori T, Kodama H, Tobe T.
    Hum Cell; 1988 Sep; 1(3):289-96. PubMed ID: 2979206
    [Abstract] [Full Text] [Related]

  • 4. [Studies on lymphokine-activated killer (LAK) cell: accumulation in tumor tissue and the therapeutic effects of adoptive immunotherapy].
    Wakizaka Y.
    Hokkaido Igaku Zasshi; 1992 Jul; 67(4):475-87. PubMed ID: 1330859
    [Abstract] [Full Text] [Related]

  • 5. Ineffectiveness of adoptive chemoimmunotherapy with lymphokine-activated killer cells, interleukin-2, and cyclophosphamide on palpable intradermal murine bladder cancer.
    Lee K, O'Donnell RW, Cockett AT.
    J Biol Response Mod; 1988 Feb; 7(1):43-53. PubMed ID: 3259620
    [Abstract] [Full Text] [Related]

  • 6. Therapeutic efficacy of sequential therapy with OK-432, cyclophosphamide, IL2-cultured lymphocytes and in vivo IL2 against advanced murine plasmacytoma.
    Kan N, Okino T, Nakanishi M, Sato K, Mise K, Yamasaki S, Teramura Y, Ohgaki K, Tobe T.
    Biotherapy; 1989 Feb; 1(3):197-206. PubMed ID: 2642023
    [Abstract] [Full Text] [Related]

  • 7. Use of human leukocyte antigen-mismatched allogeneic lymphokine-activated killer cells and interleukin-2 in the adoptive immunotherapy of patients with malignancies.
    Kimoto Y.
    Hum Cell; 1992 Sep; 5(3):226-35. PubMed ID: 1467321
    [Abstract] [Full Text] [Related]

  • 8. [Effect of combined immunotherapy using two different BRMs; OK-432 and IL-2-cultured lymphocytes].
    Kan N, Hori T, Ohgaki K, Inamoto T, Kodama H, Tobe T.
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1298-306. PubMed ID: 3488027
    [Abstract] [Full Text] [Related]

  • 9. [Improved therapeutic effect of sequential immunotherapy with cyclophosphamide, large doses of OK-432 and recombinant interleukin-2 in breast cancer patients with disseminated metastatic liver tumors].
    Akimoto M, Nishihira T, Hirakawa H, Abe M, Ohuchi N, Mori S, Kumagai K.
    Nihon Geka Gakkai Zasshi; 1991 Jan; 92(1):64-74. PubMed ID: 2014029
    [Abstract] [Full Text] [Related]

  • 10. [Experimental study on the optimal treatment schedule for combination of BRM (immunostimulators, cultured killer cells or interleukin-2) and chemotherapy].
    Kan N, Okino T, Satoh K, Mise K, Teramura Y, Yamasaki S, Harada T, Ohgaki K, Tobe T.
    Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1421-7. PubMed ID: 2389941
    [Abstract] [Full Text] [Related]

  • 11. Adoptive immunotherapy with recombinant interleukin 2, LAK and TIL.
    Kurnick JT, Kradin RL.
    Allergol Immunopathol (Madr); 1991 Aug; 19(5):209-14. PubMed ID: 1811418
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Adoptive immunotherapy in patients with multiple hepatic cancers using lymphokine activated killer cells (LAK) and interleukin-2].
    Kanai T, Monden M, Takeda T, Gotoh M, Sakon M, Umeshita K, Hasuike Y, Sakita I, Nakano H, Yoshida T.
    Gan To Kagaku Ryoho; 1993 Aug; 20(11):1457-60. PubMed ID: 8396896
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Lymphokine-activated killer cell adoptive immunotherapy for cancer treatment and its significance].
    Toge T, Yamaguchi Y.
    Hum Cell; 1992 Sep; 5(3):218-25. PubMed ID: 1334695
    [Abstract] [Full Text] [Related]

  • 17. Mechanisms of adoptive immunotherapy: improved methods for in vivo tracking of tumor-infiltrating lymphocytes and lymphokine-activated killer cells.
    Wallace PK, Palmer LD, Perry-Lalley D, Bolton ES, Alexander RB, Horan PK, Yang JC, Muirhead KA.
    Cancer Res; 1993 May 15; 53(10 Suppl):2358-67. PubMed ID: 8485722
    [Abstract] [Full Text] [Related]

  • 18. Adoptive immunotherapy in tumor-bearing mice with OK-432-induced killer cells.
    Ujiie T.
    Jpn J Exp Med; 1988 Apr 15; 58(2):109-14. PubMed ID: 3261814
    [Abstract] [Full Text] [Related]

  • 19. [Adoptive immunotherapy of murine tumors using cultured syngeneic tumor-bearer-spleen cells. II: Therapeutic effect of cultured lymphocytes against malignant ascites and its augmentation by the streptococcal preparation, OK 432].
    Kan N, Inamoto T, Hori T, Nio Y, Tsuchitani T, Kodama H, Tobe T, Ohgaki K.
    Nihon Gan Chiryo Gakkai Shi; 1985 May 20; 20(4):784-96. PubMed ID: 3877129
    [No Abstract] [Full Text] [Related]

  • 20. Adoptive immunotherapy of advanced solid tumors: an eight year clinical experience.
    Semino C, Martini L, Queirolo P, Cangemi G, Costa R, Alloisio A, Ferlazzo G, Sertoli MR, Reali UM, Ratto GB, Melioli G.
    Anticancer Res; 1999 May 20; 19(6C):5645-9. PubMed ID: 10697634
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.